- Recent Funding
- Investors
- 4BIO Capital
4BIO Capital portfolio
4BIO Capital has 7 portfolio companies on record at Recent Funding, with 3 investments in the last 12 months.
About this page
It is a venture capital firm based in London, GB, founded in 2024. It led 3 of the 4 rounds it joined. Its most recent investment on record is Oyster Therapeutics's $60M Series A round in November 2026, which it led, alongside Global Brain Corporation, Eli Lilly, Mass General Brigham Ventures and 5 others. By category, its portfolio leans toward Health and bio (7) and Logistics and mobility (1). It has co-invested with Eli Lilly, Mission BioCapital and Global Brain Corporation, most often Eli Lilly (2 rounds).
About 4BIO Capital
What 4BIO Capital invests in
- Health and bio · 7 · 100%
- Logistics and mobility · 1 · 14%
4BIO Capital recent investments
| Company | Round | Date | Alongside |
|---|---|---|---|
| Series A · $60M · lead | Global Brain Corporation, Eli Lilly, Mass General Brigham Ventures +5 | ||
| Series A · $103M | UPMC Enterprises, Deep Track Capital, Biogen New Ventures +4 | ||
| Seed · $33M · lead | AbbVie, BrightEdge - American Cancer Society, Eli Lilly +3 | ||
| Series A · $75.5M · lead | Bioqube Ventures, Surveyor Capital, Hadean Ventures (lead) +5 |
How 4BIO Capital invests
4BIO Capital portfolio companies
OOyster Therapeutics$60MSeries A · Nov 2026
EEstuary Biotherapeutics$103MSeries A · Oct 2026
CCloverleaf Bio$33MSeed · Sep 2026
AActithera$75.5MSeries A · Jul 2025
AAptadir Therapeuticsbacker
UUndecimal Biobacker
VViaNautisbacker
| Company | Round with 4BIO Capital | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series A · $60M · lead | $60M | Nov 10, 2026 Series A |
Health and bio |
Series A · $103M | $103M | Oct 16, 2026 Series A |
Health and bio |
Seed · $33M · lead | $33M | Sep 8, 2026 Seed |
Health and bio |
Series A · $75.5M · lead | $75.5M | Jul 9, 2025 Series A |
Health and bio |
backer | $45M | Sep 29, 2026 Seed |
Health and bio |
backer | $18M | Oct 13, 2026 Seed |
Health and bio |
backer | $25M | Oct 31, 2024 Series A |
Most frequent co-investors
EEli Lilly2 shared rounds · last Nov 10, 2026
MMission BioCapital2 shared rounds · last Nov 10, 2026
GGlobal Brain Corporation1 shared round · last Nov 10, 2026
OOxford Science Enterprises1 shared round · last Nov 10, 2026
MMass General Brigham Ventures1 shared round · last Nov 10, 2026
SSyncona Partners LLP1 shared round · last Nov 10, 2026
CCE Ventures1 shared round · last Nov 10, 2026
AActium Group1 shared round · last Nov 10, 2026GGV1 shared round · last Oct 16, 2026
RRA Capital Management1 shared round · last Oct 16, 2026
DDeep Track Capital1 shared round · last Oct 16, 2026
PPivotal bioVenture Partners1 shared round · last Oct 16, 2026
Similar investors
IIntrepid Growth Partners7 companies · 6 deals in 12 mo
..406 Ventures7 companies · 5 deals in 12 mo
IInnovestor7 companies · 4 deals in 12 mo
TTCG Crossover7 companies · 4 deals in 12 mo
TTesi7 companies · 4 deals in 12 mo
UUniversity of Oxford7 companies · 4 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.
Share is of the 4 rounds on Recent Funding that name 4BIO Capital. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists 4BIO Capital, which is a subset of its real portfolio. API: /api/v1/investors/4bio-capital (get a free API key). More: the most active VC firms and new venture capital funds.
The week's top funded startups and market insights, in your inbox every Monday.
Unsubscribe anytime · privacy